Novo Nordisk seeks label update for Fiasp in children
Novo Nordisk has submitted applications to both US and EU regulators for use of its fast-acting insulin Fiasp in children.
Read More
Tag: label update
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
